De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Stryker Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kevin Lobo

Algemeen directeur

US$20.8m

Totale compensatie

Percentage CEO-salaris	6.7%
Dienstverband CEO	12yrs
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	6.1yrs
Gemiddelde ambtstermijn bestuur	6.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kevin Lobo's beloning veranderd ten opzichte van Stryker's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	US$21m	US$1m	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$19m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$16m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$13m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$15m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$14m	US$1m	US$1b

Compensatie versus markt: De totale vergoeding ($USD 20.77M ) Kevin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 5.68M ).

Compensatie versus inkomsten: De vergoeding van Kevin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kevin Lobo (59 yo)

12yrs

Tenure

US$20,767,847

Compensatie

Mr. Kevin A. Lobo has been the Chief Executive Officer of Stryker Corporation since October 1, 2012 and serves as its President since October 01, 2021. He serves as Chairman of the Board at The Advanced Me...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Lobo	Chairman	12yrs	US$20.77m	0.026% MX$ 717.4m
Glenn Boehnlein	VP & CFO	8.5yrs	US$6.84m	0.0012% MX$ 31.5m
Viju Menon	Group President of Global Quality & Operations	6.5yrs	US$4.47m	0.0024% MX$ 66.0m
J. Pierce	Group President of MedSurg & Neurotechnology	6.2yrs	US$6.49m	0.015% MX$ 414.9m
Spencer Stiles	Group President of Orthopaedics & Spine	6.2yrs	US$6.49m	0.014% MX$ 377.2m
William Berry	VP & Chief Accounting Officer	3.2yrs	geen gegevens	0.00078% MX$ 21.2m
Robert Cohen	CTO and VP of Global R&D - Joint Replacement	no data	geen gegevens	geen gegevens
Alan Douville	VP, Chief Information Officer & Chief Information Security Officer	6.1yrs	geen gegevens	geen gegevens
Jason Beach	Vice President of Finance & Investor Relations	2.3yrs	geen gegevens	geen gegevens
Robert Fletcher	VP & Chief Legal Officer	5.5yrs	US$2.24m	0.0024% MX$ 66.6m
Dana McMahon	VP & Chief Compliance Officer	no data	geen gegevens	geen gegevens
Yin Becker	VP of Communications	5.8yrs	geen gegevens	0.0082% MX$ 223.4m

6.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SYK * is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Lobo	Chairman	12yrs	US$20.77m	0.026% MX$ 717.4m
Lisa Skeete Tatum	Independent Director	4.4yrs	US$319.25k	0.00085% MX$ 23.1m
Howard Cox	Director Emeritus	6.4yrs	US$38.86k	geen gegevens
John Brown	Chairman Emeritus	no data	US$286.99k	5.26% MX$ 143.0b
Ronda Stryker	Independent Director	40.8yrs	US$319.25k	4.83% MX$ 131.3b
Mary Brainerd	Independent Director	7.2yrs	US$334.25k	0.0015% MX$ 41.6m
Allan Golston	Independent Director	13.8yrs	US$334.25k	0.0039% MX$ 106.2m
Sherilyn S. McCoy	Lead Independent Director	6.4yrs	US$359.25k	0.00022% MX$ 6.0m
Rajeev Suri	Independent Director	6.4yrs	US$319.25k	0.0014% MX$ 37.2m
Giovanni Caforio	Independent Director	3.8yrs	US$319.25k	0.00067% MX$ 18.2m
Andrew Silvernail	Independent Director	10.9yrs	US$339.25k	0.0015% MX$ 39.7m
Rachel Ruggeri	Independent Director	less than a year	geen gegevens	0.000010% MX$ 271.7k

6.4yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SYK * wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.4 jaar).

Stryker Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Key Executive recently sold Mex$4.2m worth of stock

VP & CFO recently sold Mex$127m worth of stock

VP & CFO recently sold Mex$55m worth of stock

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Treace Medical Concepts, Inc. Files Lawsuit Against Stryker Corporation and Its Subsidiary Wright Medical Technology, Inc

Stryker Corporation (NYSE:SYK) completed the acquisition of Vertos Medical Inc.

Upcoming dividend of US$0.80 per share

Stryker Corporation (NYSE:SYK) acquired NICO Corporation.

Stryker Corporation (NYSE:SYK) completed the acquisition of Care.ai inc.

Stryker Corporation (NYSE:SYK) acquired The Osteotomy Truss System (OTS) and Ankle Truss System of 4WEB Inc.

Key Executive recently sold Mex$4.2m worth of stock

Stryker Corporation (NYSE:SYK) entered into a definitive agreement to acquire Vertos Medical Inc.

Stryker Corporation (NYSE:SYK) agreed to acquire Care.ai inc.

Second quarter dividend of US$0.80 announced

Stryker Announces Launch of Pangea Plating System

VP & CFO recently sold Mex$127m worth of stock

Second quarter 2024 earnings released: EPS: US$2.17 (vs US$1.94 in 2Q 2023)

Stryker's Spine Guidance 5 Software Featuring Copilot Receives 510(K) Clearance from FDA

Stryker Corporation (NYSE:SYK) completed the acquisition of Artelon, Inc.

Stryker Corporation to Report Q2, 2024 Results on Jul 30, 2024

Stryker Releases Lifepak 35 Monitor/Defibrillator

Stryker Corporation (NYSE:SYK) agreed to acquire Artelon, Inc.

First European Announces That Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

VP & CFO recently sold Mex$55m worth of stock

First quarter dividend of US$0.80 announced

Stryker Corporation Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$2.07 (vs US$1.56 in 1Q 2023)

Insufficient new directors

Insufficient new directors

Stryker Corporation to Report Q1, 2024 Results on Apr 30, 2024

Stryker Launches Gamma4 Hip Fracture Nailing System in Europe

Upcoming dividend of US$0.80 per share

Insufficient new directors

Fourth quarter dividend of US$0.80 announced

Independent Director recently sold Mex$1.7b worth of stock

Stryker Announces the Launch of Prophecy Footprint, an Expansion of the Prophecy Surgical Planning System, Offering Comprehensive Surgical Planning Across the Entire Foot

Full year 2023 earnings released: EPS: US$8.34 (vs US$6.24 in FY 2022)

Stryker Corporation Provides Earnings Guidance for the Year 2024

Insufficient new directors

Upcoming dividend of US$0.80 per share at 1.0% yield

Stryker Corporation (NYSE:SYK) executed a binding offer to acquire Serf from SAS Menix.

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Stryker Corporation Declares Quarterly Dividend, Payable on January 31, 2024

VP & Chief Accounting Officer recently sold Mex$2.9m worth of stock

Independent Director recently sold Mex$8.8m worth of stock

Stryker Corporation Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.82 (vs US$2.16 in 3Q 2022)

Stryker to Showcase Q Guidance System with Spine Guidance Software

Stryker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker Corporation Releases Its Next-Generation of Advanced Surgical Cameras

Stryker’S Pangea Systems Receive Food & Drug Administration Clearance

Stryker Corporation Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.94 (vs US$1.73 in 2Q 2022)

Stryker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

Independent Director recently sold Mex$5.1m worth of stock

Stryker Corporation Declares Quarter Dividend, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.56 (vs US$0.85 in 1Q 2022)

Stryker’s Q Guidance System for Cranial Applications Receives FDA Clearance

Independent Director recently sold Mex$2.7b worth of stock

Stryker Declares Quarterly Dividend, Payable on April 28, 2023

VP & CFO recently sold Mex$127m worth of stock

Full year 2022 earnings released: EPS: US$6.24 (vs US$5.29 in FY 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2023

Stryker Corporation to Report Q4, 2022 Results on Jan 31, 2023

Stryker Launches Citrefix™ Suture Anchor System

Investor sentiment improved over the past week

Stryker Corporation Declares Quarterly Dividend, Payable January 31, 2023

Stryker Opens the OR of the Future for Customers to Experience Tomorrow's OR

Stryker Corporation Provides Earnings Guidance for the Year 2022

Stryker Corporation Launches Monterey AI Interbody System with New Pre-Clinical Data